IBI310 Clinical Trials

2 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 1Phase 2/3: 1

Top Sponsors

Peking University1
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.1

Indications

Cancer2
Liver Disease1
Hepatocellular Carcinoma (HCC)1
Neuroendocrine Neoplasm1
Liver Cancer1

Other2 trials

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Phase 2/3

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.